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Cystic Fibrosis in Context: A Look Into Patient Advocacy, Race, Genetics, and Big Pharma
I. Introduction
I was diagnosed with cystic fibrosis about ten years ago, which is one of the most
common life threatening genetic diseases with about 70,000 people having CF across the world.
CF causes the production of heavy mucus that leads to pulmonary and pancreatic problems and
involves dozens of daily treatments and medications. Through my experience as a white person
with a disease where most patients are European, I have always wanted to complete more
concrete research into what the implications of CF being considered a “white” disease are.
Growing up I saw the way that the time my mom had to get involved with the CF Foundation
and the connections she had through work with others with time and money helped with our
fundraising efforts. It is the time, money, and connections we have that stem from my family’s
racial and economic privilege that has helped with our advocacy efforts and the organizing of
thousands of others in our community. This was the impetus in wanting to look at the struggles
and inequities in patient advocacy and how race can compound these obstacles to patients having
their voices heard.
The neoliberal approach to the American healthcare system puts in place a priority to act
based on financial incentives instead of real life struggle and experience. This neglect to listen to
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people’s personal experiences makes it more difficult for patient advocates to have their voices
heard over those of pharmaceutical executives (Panofsky 2011). The struggle for advocates to be
heard by anyone making decisions that will affect their lives are further compounded by systemic
racism that inhibits people’s ability to be heard by scientists, scholars, doctors, and policy
makers. This racial component is seen most clearly through the struggles of people with sickle
cell disease, which many consider to be a “black” disease (Wailoo 2006). Sickle cell disease is
another one of the most common life threatening genetic disorders and causes patients to
experience severe pain due to the abnormal type of hemoglobin in their red blood cells (What is
Sickle Cell Disease; Grob 2008). The hemoglobin causes their blood cells to sometimes become
sickled and reduces the blood cells ability to pass through small blood vessels, which cuts off
blood from body tissue and causes pain. This disease constituency has experienced obstacles
with trust in the medical system, struggles with access to time and money, and dangerous myths
about the community lacking agency and being “badly behaved” (Benjamin 2013). On the other
hand, the CF community being mostly white people gives more of an opportunity for patients to
get involved with advocacy and meet all their medical needs (Wailoo 2006). At the same time,
this generalization about the CF community having all white patients creates an even smaller
space for the voices of people of color that have CF. In order for disease advocacy to flourish,
scientists need to focus on the voices of patients in the context of societal issues, which means
scientists need to seek out voices and not just acknowledge the ones coming to them.
In this paper, I am going to provide an understanding of patient advocacy organizations
with a focus on the comparison between cystic fibrosis and sickle cell disease to highlight these
broader themes. I will start by looking at the way that patient advocacy organizations and
scientist-patient relationships are built. After getting an idea of this advocacy infrastructure, I am
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going to bring in information about how the racial composition of genetic diseases creates further
complications with the process of advocacy. Then I am going to look at how stem cell
technologies and treatments highlight how scientists and scholars take control of research and
neglect patient voices, and discuss the way this issue is worsened for sickle cell patients when it
comes to understanding the opposition to stem cell transplants. Next, I will analyze
pharmaceutical industries and look at the way they operate under neoliberalism to reinforce
advocacy inequities and create problems with access to drugs and treatments.
II. Patient Advocacy
The infrastructure of patient advocacy and scientist-patient relationships set the
groundwork for health mobilization success. With more recent opportunities to create digital
infrastructure, the way that patient advocacy has worked is forever changed, but the deep seated
inequities on racial and economic lines still exist in how disease advocacy operates. Despite
these digital changes, there are still disparities between patient and scientist influence or
academic expertise vs. lived expertise that play a role in the difficulties of health advocacy
(Epstein 2016; Panofsky 2011). Even questions of mobilizing the grassroots vs. letting corporate
industry advantage take over to funnel more money into research and care for a particular disease
are more pertinent than ever given the increasing power of corporations and the pharmaceutical
industry in the American political system (Panofsky 2011). To understand the infrastructure of
patient advocacy organizations, it is important to look at how PAO’s work, the history of health
mobilization, and the future of patient organizing in a digital world.
PAO’s are a critical part of health mobilization that operate as the middle man between a
grassroots patient base and a bureaucratic organization run by scientists and research experts
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(Panofsky 2011). PAO’s can range anywhere from “mom and pop” groups started by a parent
who realizes their child’s rare disease has no organization to a PAO running for the most
common disease in America. PAO’s also give disease communities the opportunity to create
larger PAOs that act as networks across other similar diseases. For example, the cystic fibrosis
community is a part of the rare disease PAO to combine forces with other diseases that have less
than 200,000 patients worldwide (Panofsky 2011). The rare disease PAO is then able to fight for
policies like the Orphan Drug Laws that incentivize scientists to look for drug and treatment
developments, despite the low pool of possible consumers in their individual disease
constituencies. PAOs can operate as more casual organizations helping patients make personal
connections that allow for sociability that motivate researchers to listen to patient priorities of
what should be researched (Panofsky 2011). PAOs can also work as more strict and regulated
groups that are seen as a stop on the way to getting a research proposal approved. The difficulty
in this kind of advocacy is that scientists often do not take people with lived experience of the
disease seriously if they don’t have the expertise about the science of the disease and the process
of doing research (Esptein 2016). This lack of trust from scientists leads many advocates to feel
the need to become lay experts to impress researchers into considering their ideas and opinions.
Both types of systems can work if done right, but each are examples of how important it is to
have an organization actively working with patients so that research can be done with priority
given to those with lived experience.
Organizations mobilizing for health changes throughout history usually focus on ideas
about organizing for a particular disease or for universal healthcare for all (Hoffman 2003).
Organizations like Act Up have realized the ways that goals of having guaranteed healthcare,
reduced drug prices, lowered deductibles and copays, and freedom to see any provider can
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overlap between the AIDS disease constituency and the rest of the health policy movement. This
act of spreading out the goals of the organization is typically not how disease constituencies
work, because they worry that making their goals too general would undermine the specificity of
certain policies and funding they need for their specific disease community. These debates over
immediate change for a disease constituency vs. more universal improvements become one of
the most difficult parts of patient organizing. This struggle also proves the way that patients feel
the responsibility to do everything themselves because there are not scientists and policy makers
actively listening to them. If scholars and politicians actually implement the more specific
community demands of these groups, advocates would have more time to organize for universal
needs outside of their disease constituency.
Ever since the Cystic Fibrosis Foundation was established, scientific experts had control
as funding came through corporate structures, but with that funding has come improved
leadership and educational opportunities and more patient involvement in the future of advocacy
and development (Panofsky 2011; Marshall 2009). The use of these corporate funds to create
patient involvement has also recently combined with digital social networks that have increased
CF patient advocacy. Part of what makes CF organizing difficult compared to other medical
conditions is the threat of cross-contamination that prohibits people with CF from being within
six feet of each other (Marshall 2009). With the rise in digital opportunity, the ability to organize
remotely or just talk with each other has increased exponentially through websites like Cystic
Life where people can create online communities and post life updates. The foundation has also
started virtual programs like Tomorrow’s Leaders that use conference calls to train young people
on how to be CF advocates. The Cystic Fibrosis Foundation has also used a public policy
program to demand basic healthcare reforms and raise awareness of the difficulties of being
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underinsured that has included teen and adult advocacy on the part of those with CF in Capitol
Hill. Through the corporate funding of CFF they have also created the Cystic Fibrosis Patient
Association to help cover insurance costs for families struggling to pay medical bills (Marshall
2009). The use of corporate funding to incorporate patients into the actions of the organization
shows that while corporate structure can create issues with patient voices, it can also be a way to
make the money necessary for patient and professional integration.
With these advances in the digital world, it has become much easier for patients to
connect with each others online and create social cohesion that “break down ‘information
monopolies’’” (Landzelius and Dumit 2006:593). Breast cancer patients and loved ones have
also had a lot of success with online self-help communities by creating relationships with others
who understand what they are going through. The communities also have records with research
and information, which includes a glossary of breast cancer terms. These kinds of educational
sources change the information landscape, allowing patients to swap information with each other
rather than solely getting it from doctors who many patients commiserate about not trusting.
Online patient run groups give people the opportunity to be each other's advocates and support
system without the struggle of being shut out from conversations with research experts or
politicians.
A lot of issues about improving patient advocacy are not frequently discussed, especially
the question of how to expand access to advocacy for more disadvantaged patients. For example,
one of the main strategies to create sociability and personal connection among patients and
scientists with the help of PAOs is conferences and formal dinners one patient called “elbow to
elbows” (Panofsky 2011). It is unrealistic that someone would be able to attend one of these
events that likely involves flying on a plane if they do not even have enough money to pay the
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expensive medical bills for themselves or a loved one. This can go for conferences and fancy
dinners, but it can also go for raising money through events and asking friends and family for
money when you don’t have a higher income social group to ask. Even social online groups are
often not used by people who are low income because they need access to a computer and many
of the people involved in these groups will take trips to meet each other that would be difficult to
do if you were struggling financially and had time constraints (Landzelius and Dumit 2006). The
issues relating to race and socioeconomic status make it clear that equal opportunity in disease
advocacy directly connects to ideas of racial inequity in health mobilization.
III. Race and Genetic Diseases
Cystic fibrosis is known as a “white disease”, while sickle cell disease is seen as a “black
disease”, and while the histories and demographics of these two diseases do prove these
associations to be true, the narrative of these two conditions has gone a lot farther than the
concrete biological facts (Wailoo 2006). Cystic fibrosis is known as a disease from Europe that
possibly started due to a genetic resistance to the European cholera outbreak, while sickle cell
disease has been tagged as starting as a genetic resistance to malaria in Africa. Genetic diseases
are inherently connected in some way to ideas of race and ethnicity, which complicate the
already difficult process of patient advocacy (Wailoo 2001; Wailoo 2006). Not only does race
impact the way that all of these elements of advocacy operate, but it also creates changes
throughout the history of organizational advocacy in how they strategize to push for access,
research, and awareness for their constituents. For diseases constituencies that are seen as
marginalized based on race, there is the additional aspect of systemic exclusion from income,
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healthcare, and expectations for fair medical practices. That systemic exclusion is why it is
integral to improving advocacy to look at the impact of societal disparities.
The politics of race that have been impacting research and legislation for both sickle cell
anemia and cystic fibrosis for decades have shifted to connect with different historical moments
in America. Growing up with cystic fibrosis, I always associated the disease with something
white people have due to its connection to Europe. I would even go into my CF clinic knowing
to avoid other people with CF due to cross-contamination risks and thought of the CF give away
as a white person with a mask on. Despite the truth that the majority of CF patients are white, CF
is a more panethnic disease then it is given credit for, largely due to the pivot in the 1990’s that
CF was a “Cacuasian disease” to stir up momentum for venture investment research (Wailoo
2006). This strategy worked because venture investment saw a group of white disease
constituents as more likely to have the money to fund this drug research, but also because CF’s
white image gave it the reputation of being the disease of the “majority of America”. This
perception of the CF community created a better justification for the researchers in why they
were doing drug experimentation for a rare disease. This idea that CF represented the population
of the “majority of America” also created a lack of racial group identity or solidarity for CF
because it wiped over any kind of ethnic or racial diversity within the CF community. Tay-Sachs
disease being seen as a Ashkenazi Jewish disease and sickle cell being seen as an African
American disease creates a sense of racial/ethnic connection that CF lacks (Wailoo 2006;
Burgess 2019).
In the 1970’s when America was in the midst of the black power movement and had just
experienced the civil rights movement, researchers framed CF as a panethnic disease to better
connect its advocacy efforts to the current moment (Wailoo 2001; Wailoo 2006). Sickle cell
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anemia has always been seen as a “black” disease and as a result it has been seen as
representative of the pain and suffering black people have experienced in America. This
connection has led to more awareness and advocacy in the hopes of rewriting wrongs of racism
in America, especially during the late 60’s and 70s . Even Richard Nixon passed legislation in
hopes to improve conditions for people with sickle cell disease and end the neglect of the pain of
black America. Unfortunately, sickle cell’s association as a “black disease” has also created
conflict in providing patients with pain management drugs when they are having what is called a
pain “crisis” because of the cultural idea of black people being more likely to get addicted to
narcotics scaring scientists and physicians (Wailoo 2006).
One of the other critical aspects of disparity between cystic fibrosis and sickle cell
anemia is the way they bring in money and attention for critical research. Cystic fibrosis has
been described as a “privileged disease” because “there were an estimated 1,155 new cases of
[sickle cell] disease [and] 1,206 of cystic fibrosis...[y]et volunteer organizations raise $1.9
million for cystic fibrosis...,but less than $100,000 for sickle cell anemia” (Wailoo 2006:63). The
fundraising that has been done for sickle cell anemia, which is a specific type of sickle cell
disease, comes in large part from groups connected to the black community due to the group
solidarity aspect of the disease (Wailoo 2001). For example, a sickle cell center in Memphis
Tennessee run by Lemuel Diggs received funding from a local black sorority and the NIH.
Ebony also used its appeal as a magazine targeting a mostly black audience to help sickle cell
gain awareness by covering stories of the families that are battling the disease everyday. Not only
did this bring recognition to the real faces behind the disease, but the article touched on
environmental triggers to disease flare ups and discussed the economic and political component
of living with an expensive disease, while being part of a marginalized racial community.
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Despite the way black solidarity can increase fundraising for sickle cell, it does not overperform
the tens of thousands of CF advocates that are more likely to have the time and money to
participate in fundraising due to the demographic makeup of the disease community.
A lot of the way that sickle cell research is framed is concerned with a disproportionate
amount of people of color struggling financially and socially due to systemic racism. This kind
of concern has caused fear that risky treatments framed as cures like bone marrow transplants are
going to be picked by families who fear the economic consequences of raising a child with sickle
cell for years to come (Wailoo 2006). The truth of bone marrow transplants is that parents with
lots of degrees are more likely to choose this risky procedure and even if the patient survives,
there is a high probability that they will develop other expensive conditions. Despite the research
not backing up this claim, the idea still permeates the school of thought for sickle cell. This kind
of worry leads many researchers to not want to target members of the sickle cell community for
more long-term cures and instead focus on more incremental changes that can make life more
manageable for people with sickle cell. CF patients are different in that they are more likely to be
focused on for experimental drug treatments because venture markets see value in a privileged
constituency who represents a washed out wide swath of American society (Wailoo 2006).
The other difficulties of life with sickle cell are endless because of a myriad of racial
inequities embedded in our culture and political institutions. One of these obstacles is the overall
lack of trust many black Americans feel towards the medical system due to the country’s history
of medical discrimination most blatantly seen in the Tuskegee experiments (Wailoo 2006). This
medical mistrust also carries into forms of control of birth that have been used in the Ashkenazi
Jewish community to reduce the birth of babies with Tay-Sachs because women of color in
America have a long history of white people controlling their reproduction (Wailoo 2006;
Sloan 11
Burgess 2019). There was even a researcher at one point who suggested that people should get
tattoos if they carry sickle cell so that they do not fall in love with another sickle cell carrier and
have a child with the disease. There is also the direct link between lack of familial income and
Medicare coverage that impacts families of color disproportionately and is part of what causes
the fundraising disparities in advocacy with organizations like the CF Foundation (Wailoo 2006).
Sickle cell is a disease that is most known for sudden increases in pain “crises” which often
involve hospitalizations. Hospital treatments for crises only serve to improve symptoms and still
cost $30,000 to $50,000 a year. Complications with staying employed and getting coverage from
work while raising a child in and out of the hospital create a cyclical effect that complicates life
with a chronic illness under systemic racial inequality (Wailoo 2006).
Solving the crisis of racial inequity in treatment and research in sickle cell does not have
clear cut and easy solutions. Similar to how issues like asthma in low income communities need
to be solved with social programs that get to the root of racial disparities, sickle cell needs to be
improved with structural social policy change to alleviate the economic and social stressors of
racism (Brown 2003). If issues like medical access and higher economic stability amongst people
of color were achieved, patients with sickle cell would have families more financially able to pay
for their medications and hospital stays. Issues like expanding Medicare access and lowering
drug costs are already more well known and have people rallying behind them. Even if these
policies passed without awareness of sickle cell, they would be helping black Americans live
with more financial comfort that would be helping people with sickle cell. While this increased
financial stability could increase the ability for sickle cell families to get involved in more
advocacy, that does not mean scientists and politicians would all of a sudden start listening to the
community. Issues relating to bias of white scientists and politicians and the overall lack of trust
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in institutions from the black community would still cause a lack of consideration of the needs of
the sickle cell community.
IV. Genetic Testing, Technology, and Treatment
Scientists owning the narratives surrounding genetic testing and technology has created a
lack of acknowledgement of social disparities creating distrust over genetic treatment for sickle
cell patients and little awareness of the complexities of newborn screening for genetic diseases
like CF (Benjamin 2013; Grob 2008). The risk of these scientific narratives stem from the
disconnect they have with patients and families that have personal experience with the disease.
This lack of patient understanding creates false justifications for why people are skeptical or
unsupportive of using new kinds of genetic testing and technology. The two aforementioned
recent advances in genetic testing and treatment, have lots of advantages seen through the help
they have been able to do for people struggling with genetic diseases, but there is much more to
these treatments than guaranteed medical help. A lot of the complexities of balancing the ethics
of these new treatments comes from a need to work with a spectrum of parents experiencing
these problems without using research as an opportunity for scientists and scholars to take further
control of the medical narrative.
Newborn screening has grown out of the prenatal screening that began about thirty years
ago and by the late 2000’s newborn screening had become so commonplace that only three states
even asked for consent to complete the test (Grob 2008). Newborn screening was initially used to
test for diseases like phenylketonuria that were threats to newborn’s health, but had universal
treatment options. After these screenings expanded in use, the genetic diseases tested for grew
with it, which means that diseases like CF that are usually not putting infants in danger and often
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do not have visible symptoms for weeks, months, or years are being tested for. Unfortunately,
scientists and scholars did not take the struggles newborn parents who have a baby that just
tested positive for a genetic disease into account (Grobb 2008).
Since a disease like CF can be asymptomatic for newborns, the difference between
“sickness” and “disease” becomes very clear as parents see a healthy baby, but know that their
child has a genetic disease. One mother in Grob’s study recalls looking at her baby and wanting
to fall in love with them, but being worried to do so because she didn’t know how long her baby
would be alive. Meanwhile, parents whose children get diagnosed with CF later on, can go
through the normal bonding development process with their child before getting the diagnosis so
that it doesn’t change the core of their relationship. Especially for first time parents, this
experience can be anxiety inducing as they try to parce what is normal for a baby vs. a possible
dangerous CF symptom. This anxiety can lead to an over reliance on doctors that expand the
medicalization process of their baby and could jeopardize the patient-doctor relationship if the
doctor feels annoyed and overwhelmed by the parents’ constant messages (Grob 2008).
The CF parents in Grob’s survey do understand the need to have the newborn screening
as an option, but said that personally they would have wanted to be able to wait for symptoms
before diagnosis. Many parents surveyed did wait to get their children tested in the future since
they had the genetic potential to have cystic fibrosis. Since I was diagnosed with CF at nine years
old, I have thought about how different my life would be if I was born a couple of years after
2001 and received an automatic newborn screening. While it might have been better for me to
live my whole life knowing I had CF instead of having to process that shift in my consciousness
and identity later, my parents have mentioned that on their end it would have probably been more
stressful for the reasons mentioned earlier about the struggles of being a parent of a newborn
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with CF. My experience matched some of the survey participants’ in that though stressful there
was a sense of relief in my diagnosis given that my parents had not been taken seriously when
concerned about my CF symptoms in the past. What this wide spectrum of experiences show
from CF parents is that families need to be included in the discussion over the rules and
legislation about newborn testing. Currently scientists only listen to a small group of active
advocates whose newborns have or could have been saved by newborn screening, and scientists
should seek out other voices touched by the issue in addition to hearing these important
experiences (Grob 2008).
There has also been a lack of sickle cell voices in explaining the reason that many
patients and families chose not to do stem cell transplants, which creates a roadblock in working
to help the sickle cell community going forward. After seeing the disparity between African
American patients and Asian American patients in receiving experimental stem cell research,
scientists came up with false justifications for these disparities by saying people of color lack
agency and the ability to comply with doctor's orders (Benjamin 2013). Research on this topic
has continued to fail to analyze the way that “social processes” create these disparities in the way
that “distrust is socially produced in the everyday experiences of patient families in and outside
of the clinic” (Benjamin 2013:2). In a similar way to how information on the disproportionate
levels of health crisis like COVID-19 in the black community can be misinterpreted as people of
color not being careful and hygenic, sickle cell research can wrongly place blame on people of
color for not having “agency” (Chowkwanyan and Reed 2020).
Many sickle cell patients not attending all appointments and using every medication is a
multifaceted issue connecting with possible struggles to pay for the medication and finding time
to pick it up, but it also relates to a societal distrust of medical professionals through horrors like
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the Tuskegee experiment (Benjamin 2013). One participant interviewed in Benjamin’s article
talks about not wanting her daughter to use an inhaler because she is unaware of the outcomes
and possible side effects it could have and has seen other sickle cell patients get over prescribed
medications that worsen their condition. Considering why these racial disparities within these
experimental stem cell treatments exist for sickle cell families can be like “sweeping up broken
glass while the... flames in their lives are left to wreak havoc” (Benjamin 2013:7). In order to be
a sickle cell advocate who is trying to expand stem cell research, families would need the time,
money, and connections to answer questions like this and get scientists to listen to them, which is
a rare combination of factors for someone in this situation.
When it comes to raising funds and grants to expand stem cell research, there is also a
large disconnect between the sickle cell community and the people involved in politics,
pharmaceuticals, and biotech companies (Benjamin 2013). Sickle cell research has often been
used politically in conjunction with the fight for racial justice, but these political rallying cries
have not always brought forward the voices of the actual patients fighting this disease. When
California tried to pass a state stem cell research proposition it did not even listen to the Sickle
Cell Disease Foundation and received backlash for being a ploy to help large biotech companies.
The other large flaw in these pushes for more stem cell funding is that none of these groups are
looking to solve the societal issues that are causing most sickle cell patients to stay away from
stem cell transplants (Benjamin 2013). This means that when care does look to more long term
solutions, it fails to fix the societal problems relating to race that are more structural and would
help people of color as whole (Wailoo 2006). These societal changes would improve sickle cell
patient’s ability to advocate for their interests and work with their doctors, but instead politicians
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are pushing for more of a treatment that will likely be rejected anyway by a large sector of the
sickle cell community.
V. Big Pharma
The pharmaceutical industry has been known to prioritize their own profits over the
needs and interests of disease communities, but this focus on profits has also created inequities in
drug development between the cystic fibrosis and sickle cell constituencies. Even though
corporate profits have been tied to medicine since the 1940’s, the era of neoliberalism that started
in the 70’s has taken the private pharmaceutical industries to a different level (Hemphill 2010;
Baker 2016).  Since the 1970’s, the patents have intensified by being held for longer amounts of
time and the international laws and regulation surrounding patents and their copyrights has
extended to international waters to match the globalization of the era (Baker 2016). As patents
have become stronger, productivity has gotten weaker, total factor productivity rate decreasing
from 1.2% in the 70’s to under 1% in the 2000’s.
Neoliberalism has also been embedded into big pharma through the orphan drug system
in order to have drug development for small disease constituencies fit the industry’s need to
make a profit. Policy like the 1984 Orphan Drug Act and tax credit incentives for big pharma to
develop drugs for small disease groups are the only way that these companies will feel they have
a reason to prioritize these groups (Hemphill 2010). Pharmaceutical companies have even caused
disease inflation where they expand what it means to be sick so that drugs that are meant for a
targeted audience can be expanded to a wider pool to increase the profits of the private
pharmaceutical industries. In order for disease constituencies to work around this disadvantage in
having a smaller demographic for drug developments that don’t match the incentive model for
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private pharmaceutical companies, they have to get creative in how they network with big
pharma.
The CF Foundation has had more support throughout history with the pharmaceutical
industry than most other disease constituencies, choosing to ally with private industry groups
through their venture pharmaceutical program with Vertex. This partnership creates a dynamic
where a nonprofit is working with a pharmaceutical company to bring in profit on both sides that
is meant to go back into research (Cohen and Raftery 2014)). CF advocacy has also benefited
from wealthy individuals like Joe O’Donnell who has a personal connection with CF and has put
on high price fundraising events to bring in money for the organization. This dynamic is also at
play in less extreme ways given the higher percentage of white people that have CF and the
realities of racial inequities in America and their impact on socioeconomic divisions. Because of
this economic advantage in industry and grassroots financial growth, the CF Foundation has
succeeded in having lots of research and drug trials and approvals compared to conditions like
SCD (Farooq 2020).
As a result of this venture pharmaceutical model, the CF Foundation has had success with
multiple drugs whose effects would have been unheard of fifteen years ago. Trials started in 2011
for ivacaftor which is the first drug in the CF community to address the underlying causes of the
CFTR protein malfunction compared to treating the symptoms of CF like Pulmozyme or
antibiotics like TOBI that were approved by the FDA in the 1990’s (CF Foundation).
Ivacaftor/Kalydeco, was then approved by the FDA in 2014 for people in the CF population that
have one out of the eight different mutations, which represented about 5% of the CF population
(Cohen and Raftery 2014). Then in 2015, Kalydeco was approved for people with one or two
F508del mutations, which accounted for 90% of the CF Foundation (Johnson 2019). Since then,
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more trials have been done to try to expand the drug to the rest of the CF community and to
expand the drug from single therapy to the double and triple combination treatments called
Symdeko and Trikafta (CF Foundation).
It is also important to mention that the 10% of the CF population that are not covered by
any of these groundbreaking drugs are disproportionately minority members of the community
that are already statistically likely to have lower life expectancies than white people with CF
(Johnson 2019). The drugs also cost $311,000 a year and even though the patent ivacaftor is on
for five years after being released and the passage of the orphan drug laws helped the drug get
created, there has not been much change to accommodate the price beyond insurance coverage
patients can hope to have through their employers (Johnson 2019; Cohen and Raftery 2014).
This venture philanthropy model that the Cystic Fibrosis Foundation took up has brought all of
these new drugs that are having drastic impacts on patients' health, but questions around access
to the drugs and the patient’s voice in a process based in corporate profits still exist. Since the
success of the CF venture pharmaceutical model in developing new drugs, many other disease
constituencies have developed similar plans, but the disparity in resources and trust in the
medical establishment that the sickle cell community has makes these kinds of private alliances
more difficult. (Farooq 2020).
VI. Conclusion
Throughout American history, patients have struggled to have their voices heard by
scientists and politicians, always feeling like they are “pitted against each other” for care
(Hoffman 2003:82). The way that research has worked has been more based on pharmaceutical
and biotech incentives then what patients have been saying should be researched and prioritized.
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Researchers and politicians have also failed to take systemic inequalities into account that are
integral to success in getting advocates’ voices across (Benjamin 2013). Patients and families
should not be begging for scraps with scientists and policy makers to have their voices heard,
and these “begging sessions” shouldn’t require a three hundred dollar plane ticket to be able to
happen in the first place (Panofsky 2011).
The people that need to act to rewrite this wrong are politicians who need to both listen to
patients and act to pass structural societal change so that racial inequities stop creating obstacles
to advocacy. It is still important to acknowledge that passing racial justice policy would still not
be enough to end this advocacy divide due to the racial prejudice through unconscious bias
impacting how willing people are to listen and act on the interests of people of color. The other
large issue when it comes to racial inequities in medicine is creating more trust in the medical
profession among the black community, which like the last issue, is not going to be fixed with
one clean and easy solution. One option to fix this predicament, is to put value and support
behind leaders who are trusted in communities of color that can encourage others to develop
more trust in the system (Godoy 2020). Another important aspect of advocacy inequity to
consider is the fact that if people with more privilege have more opportunities to get involved,
the young people around them are more likely to have first hand experience seeing someone do
this kind of work. Giving this same kind of education in schools may allow people who don’t
know anyone doing disease advocacy to see what it means and how important it is to our
healthcare system.
Patients have been working hard for decades to have their voices heard for improvements
on issues that impact their lives and those of others, whether they have a disease that affects ten
other people or ten million (Panofsky 2011). These people are working for their own futures and
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deserve better than getting neglected for gains in pharmaceutical revenue. Despite these
difficulties, it does look like there is hope for disease constituencies going forward. One source
of hope comes from the new opportunities for patients and families to use technology for
activism and social connection that allow patients to “break down ‘information monopolies’” and
make their voices heard (Landzelius and Dumit 2006:593). With issues like racial justice and the
inept nature of the American healthcare system coming to a boiling point in 2020 with protests
over police brutality and the dangerous holes in our healthcare system being highlighted by
COVID-19, it looks like a perfect storm for changing the neglect of patients and especially
patients of color. It looks like 2021 could bring change and scientists and politicians could work
with patients to regain trust by being a part of that change. In order for scientists and politicians
to step up and actually help patients, they can’t just listen to the people who can fly out to D.C.
for conferences and political action days, but need to seek out voices that may have never been
heard before.
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